Premium
Multiplexed fluorescence in situ hybridization–based detection of circulating tumor cells: A novel liquid‐based technology to facilitate accurate and early identification of non–small cell lung cancer patients
Author(s) -
Zhu Yili,
Lowe Alarice ChengYi
Publication year - 2020
Publication title -
cancer cytopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.29
H-Index - 57
eISSN - 1934-6638
pISSN - 1934-662X
DOI - 10.1002/cncy.22277
Subject(s) - medicine , fluorescence in situ hybridization , lung cancer , malignancy , circulating tumor cell , in situ , pathology , cancer , cancer research , radiology , biology , gene , metastasis , genetics , physics , chromosome , meteorology
Multiplexed fluorescence in situ hybridization–based circulating tumor cell (CTC) technology detects cytogenetic abnormalities in patients who are at risk for non–small cell lung cancer with high accuracy. Combined with low‐dose computed tomography, this CTC technology can efficiently rule out malignancy in at‐risk patients with benign pulmonary nodules.